Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies.

× No keyword cloud information.

14 in total

Review 1. Vaccine design for severe acute respiratory syndrome coronavirus.

Authors: Yuxian He; Shibo Jiang
Journal: Viral Immunol Date: 2005 Impact factor: 2.257

2. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines.

Authors: Yuxian He; Yusen Zhou; Hao Wu; Baojun Luo; Jingming Chen; Wanbo Li; Shibo Jiang
Journal: J Immunol Date: 2004-09-15 Impact factor: 5.422

3. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.

Authors: Himani Bisht; Anjeanette Roberts; Leatrice Vogel; Alexander Bukreyev; Peter L Collins; Brian R Murphy; Kanta Subbarao; Bernard Moss
Journal: Proc Natl Acad Sci U S A Date: 2004-04-19 Impact factor: 11.205

Review 4. SARS vaccine development.

Authors: Shibo Jiang; Yuxian He; Shuwen Liu
Journal: Emerg Infect Dis Date: 2005-07 Impact factor: 6.883

5. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.

Authors: Yuxian He; Qingyu Zhu; Shuwen Liu; Yusen Zhou; Baoan Yang; Jiaming Li; Shibo Jiang
Journal: Virology Date: 2005-03-30 Impact factor: 3.616

6. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.

Authors: Shuwen Liu; Gengfu Xiao; Yibang Chen; Yuxian He; Jinkui Niu; Carlos R Escalante; Huabao Xiong; James Farmar; Asim K Debnath; Po Tien; Shibo Jiang
Journal: Lancet Date: 2004-03-20 Impact factor: 79.321

7. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.

Authors: Alexander Bukreyev; Elaine W Lamirande; Ursula J Buchholz; Leatrice N Vogel; William R Elkins; Marisa St Claire; Brian R Murphy; Kanta Subbarao; Peter L Collins
Journal: Lancet Date: 2004-06-26 Impact factor: 79.321

8. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine.

Authors: Yuxian He; Yusen Zhou; Shuwen Liu; Zhihua Kou; Wenhui Li; Michael Farzan; Shibo Jiang
Journal: Biochem Biophys Res Commun Date: 2004-11-12 Impact factor: 3.575

9. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection.

Authors: Yuchun Nie; Guangwen Wang; Xuanling Shi; Hong Zhang; Yan Qiu; Zhongping He; Wei Wang; Gewei Lian; Xiaolei Yin; Liying Du; Lili Ren; Jianwei Wang; Xiong He; Taisheng Li; Hongkui Deng; Mingxiao Ding
Journal: J Infect Dis Date: 2004-08-02 Impact factor: 5.226

Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies.

Review 1. Vaccine design for severe acute respiratory syndrome coronavirus.

2. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines.

3. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.

Review 4. SARS vaccine development.

5. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.

6. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.

7. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.

8. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine.

9. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection.

10. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2.

Review 1. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.

2. Immunogenicity difference between the SARS coronavirus and the bat SARS-like coronavirus spike (S) proteins.

3. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.

4. Identification of immunogenic determinants of the spike protein of SARS-like coronavirus.